← boardnext 2026-10-15
SLDB
Solid Biosciences Inc.distress 4/10 · elevated risk$7.89-3%today-29% from 52w high
Lead: Duchenne muscular dystrophy · est. market ~$4B (approx, global)
Revenue
pre-revenue
Liquidity
$297M
Runway
1.7 yrs
Shares 1y
+26%
Price & events
+15.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.6%
1D
-12.8%
1W
-10.2%
1M
-4.0%
3M
+19.5%
6M
+16.7%
1Y
-14.2%
2Y
-81.1%
5Y
-93.3%
All
Overview
- Market Cap
- $776.77M
- Volume
- 101.10K
- 52 Week Range
- $3.93 – $11.15
- Total Shares
- 98.45M
- Float Shares
- 51.04M
- Short %
- 21.35%
- % Held by Insiders
- 0.74%
- % Held by Institutions
- 104.69%
- RVOL
- 0.04x
- Beta
- 2.36
Pipeline stages · 1 programs
SGT-003
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10-15 Estimated 50% readout ~2026-11-29 | Phase 1/2 | SGT-001fast trackrare pediatric | Duchenne Muscular Dystrophy | — | active not recruiting |
| 2027-05-06 Estimated 50% readout ~2027-06-20 | Phase 1/2 | SGT-003fast trackrare pediatric | Duchenne Muscular Dystrophy | — | recruiting |
| 2029-01 Estimated 50% readout ~2029-03-17 | Phase 3 | SGT-003fast trackrare pediatric | Duchenne Muscular Dystrophy | — | recruiting |
Catalyst news & presentations · 9
- second half of 2026Guided 55%regulatory submissionFiled (NDA/BLA)SGT-601 · Submit IND to FDA for SGT-601SEC 8-K
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
- early 2026enrollment completesecondaryPhase 1/2SGT-003 · Expects to dose a total of 30 participants by early 2026.SEC 8-K
- first quarter of 2026trial initiationsecondaryPhase 3SGT-003 · First participant dosing in Phase 3 IMPACT DUCHENNE trial.SEC 8-K
- 2026-02-09fda agreementSGT-003 · FDA alignment on Phase 3 IMPACT DUCHENNE trial design.SEC 8-K
- fourth quarter of 2025enrollment completesecondaryPhase 1/2SGT-003 · Approximately 20 participants dosed in INSPIRE DUCHENNE trialSEC 8-K
- second half of 2025trial initiationsecondaryPhase 1SGT-212 · Initiate Phase 1b clinical trial of SGT-212SEC 8-K
- early second quarter of 2025enrollment completesecondaryPhase 1/2SGT-003 · At least 10 participants dosed in INSPIRE DUCHENNE trialSEC 8-K
- first half of 2025regulatory submissionFiled (NDA/BLA)SGT-501 · Submit IND to FDA for SGT-501SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $18 (+122% upside) · 12 analysts
- 2026-06-03HC Wainwright & Co.Buy
- 2026-05-18WedbushOutperform
- 2026-05-13WedbushOutperform
- 2026-05-13Piper SandlerOverweight
- 2026-03-25JP MorganOverweight
- 2026-03-23HC Wainwright & Co.Buy
Competitors — Duchenne muscular dystrophy
- EWTXEdgewise Therapeutics, Inc.$4.1B · D4
- DYNDyne Therapeutics, Inc.$3.3B · D4
- SRPTSarepta Therapeutics, Inc.$1.6B · D2
- WVEWave Life Sciences Ltd.$1.1B · D1
- CAPRCAPRICOR THERAPEUTICS, INC.$1.1B · D4
- RGNXREGENXBIO Inc.$508M · D7
- TRDAEntrada Therapeutics, Inc.$236M · D2
- DTILPRECISION BIOSCIENCES INC$185M · D6
- PEPGPepGen Inc.$133M · D6
- CPIXCUMBERLAND PHARMACEUTICALS INC$102M · D0
Recent news
- 2026-07-22SLDB stock trades around recent lows as Solid Biosciences updates gene therapy pipeline - Ad-hoc-news.de
- 2026-07-19Solid Biosciences (SLDB) Proxy filing Summary - Quartr
- 2026-07-16Solid Biosciences (SLDB) Proxy filing Summary - Quartr
- 2026-07-13Solid Biosciences (SLDB) AGM 2026 Summary - Quartr
- 2026-07-12Solid Biosciences (SLDB) Proxy filing Summary - Quartr
- 2026-07-11How Investors May Respond To Solid Biosciences (SLDB) Joining Multiple Russell Growth Indices - Sahm
- 2026-07-10How Investors May Respond To Solid Biosciences (SLDB) Joining Multiple Russell Growth Indices - simplywall.st
- 2026-07-07Form 4 Solid Biosciences LLC For: 7 July By Investing.com - Investing.com Nigeria
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.